JP6883688B2 - バイオアベイラビリティが高いアルボシジブプロドラッグ - Google Patents
バイオアベイラビリティが高いアルボシジブプロドラッグ Download PDFInfo
- Publication number
- JP6883688B2 JP6883688B2 JP2020075973A JP2020075973A JP6883688B2 JP 6883688 B2 JP6883688 B2 JP 6883688B2 JP 2020075973 A JP2020075973 A JP 2020075973A JP 2020075973 A JP2020075973 A JP 2020075973A JP 6883688 B2 JP6883688 B2 JP 6883688B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- combination according
- pharmaceutical combination
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CN(CC1)CC(*)C1c(c(OC(c1ccccc1Cl)=C1)c(c(O*)c2)C1=O)c2O* Chemical compound CN(CC1)CC(*)C1c(c(OC(c1ccccc1Cl)=C1)c(c(O*)c2)C1=O)c2O* 0.000 description 1
- NQPQYVJGRPVZDF-UHFFFAOYSA-N CN(CCC1c(c(OC(c2ccccc2Cl)=C2)c(c(O)c3)C2=O)c3O)CC1OP(O)(O)=O Chemical compound CN(CCC1c(c(OC(c2ccccc2Cl)=C2)c(c(O)c3)C2=O)c3O)CC1OP(O)(O)=O NQPQYVJGRPVZDF-UHFFFAOYSA-N 0.000 description 1
- MDGQQPJHLWPFFF-UHFFFAOYSA-N OC(CN(CC12[BrH]C1C2)CC1)C1c(c(OC(c1ccccc1Cl)=C1)c(c(O)c2)C1=O)c2OP(O)(O)=O Chemical compound OC(CN(CC12[BrH]C1C2)CC1)C1c(c(OC(c1ccccc1Cl)=C1)c(c(O)c2)C1=O)c2OP(O)(O)=O MDGQQPJHLWPFFF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Description
技術分野
本発明は、一般に、アルボシジブのホスフェートプロドラッグおよびがん処置のためのその使用に関する。
サイクリン依存性キナーゼ(CDK)は、細胞周期のタイミングおよび協調を調節する重要な制御因子である。CDKは、その必須のサイクリンパートナーと可逆的な複合体を形成して、細胞周期における重大な時点からの移行を調節する。例えば、活性化されたCDK4−サイクリンD1複合体は細胞周期のG1期の通過を調節し、CDK1−サイクリンB1複合体は細胞周期の***期に入るのを調節する。内因性サイクリン依存性キナーゼ阻害タンパク質(CDKI)は、CDK成分またはサイクリン成分のいずれかに結合し、複合体のキナーゼ活性を阻害することが公知である。黒色腫、膵臓がん、および食道がんなどの多くの腫瘍において、これらの天然CDKIは存在しないか変異している。したがって、選択的CDKインヒビターは、有効な化学治療剤である可能性がある。
簡単には、本発明の実施形態は、アルボシジブ親化合物と比較してバイオアベイラビリティが高いアルボシジブのホスフェートプロドラッグを提供する。したがって、一実施形態では、下記の構造(I):
一実施形態において、例えば、以下の項目が提供される。
(項目1)
下記の構造(I):
R1、R2、またはR3のうちの1つは−P(=O)(OH)2であり、R1、R2、およびR3のうちの他の2つはそれぞれHである、化合物またはその立体異性体、互変異性体、もしくは薬学的に許容され得る塩。
(項目2)
下記の構造(I’):
(項目3)
下記の構造(IA):
(項目4)
下記の構造(IA’):
(項目5)
下記の構造(IB):
(項目6)
下記の構造(IB’):
(項目7)
下記の構造(IC):
(項目8)
下記の構造(IC’):
(項目9)
項目1〜8のいずれか1項に記載の化合物の薬学的に許容され得る塩。
(項目10)
前記薬学的に許容され得る塩が塩基付加塩である、項目9に記載の薬学的に許容され得る塩。
(項目11)
前記薬学的に許容され得る塩がナトリウム塩である、項目10に記載の薬学的に許容され得る塩。
(項目12)
前記薬学的に許容され得る塩が酸付加塩である、項目9に記載の薬学的に許容され得る塩。
(項目13)
前記薬学的に許容され得る塩が塩酸塩である、項目12に記載の薬学的に許容され得る塩。
(項目14)
薬学的に許容され得る担体または賦形剤および項目1〜13のいずれか1項に記載の化合物を含む医薬組成物。
(項目15)
前記医薬組成物が経口送達のために製剤化されている、項目14に記載の医薬組成物。
(項目16)
サイクリン依存性キナーゼ(CDK)の過剰発現に関連する疾患の処置を、それを必要とする哺乳動物において行う方法であって、治療有効量の項目1〜13のいずれか1項に記載の化合物または項目14もしくは15のいずれか1項に記載の組成物を前記哺乳動物に投与する工程を含む、方法。
(項目17)
前記疾患ががんである、項目16に記載の方法。
(項目18)
前記がんが血液学的がんである、項目17に記載の方法。
(項目19)
前記血液学的がんが、急性骨髄白血病(AML)、多発性骨髄腫、濾胞性リンパ腫、急性リンパ芽球性白血病(ALL)、慢性リンパ性白血病(CLL)、および非ホジキンリンパ腫から選択される、項目18に記載の方法。
(項目20)
前記血液がんが急性骨髄白血病(AML)である、項目19に記載の方法。
(項目21)
前記血液学的がんが慢性リンパ性白血病(CLL)である、項目19に記載の方法。
(項目22)
前記血液学的がんが骨髄異形成症候群(MDS)である、項目18に記載の方法。
(項目23)
前記方法が、項目1〜13のいずれか1項に記載の化合物または項目14もしくは15のいずれか1項に記載の組成物を前記哺乳動物に経口投与する工程を含む、項目16〜22のいずれか1項に記載の方法。
以下の説明において、本発明の種々の実施形態の充分な理解をもたらすために特定の具体的な詳細な説明を示す。しかしながら、当業者には、本発明がこれらの詳細な説明なしに実施され得ることが理解されよう。
(Elsevier,Amsterdam)を参照)。プロドラッグの考察は、Higuchi, T.ら, "Pro-drugs asNovelDelivery Systems," A.C.S. Sy
mposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press,1987に示されている。これらの両方ともが、参考により本明細書中に全体が援用される。
(i)哺乳動物において、該疾患または状態が発生するのを予防すること(特に、このような哺乳動物が該状態に罹りやすいが、該状態を有するとは未だ診断されていない場合);
(ii)該疾患または状態を抑制すること、すなわち、その発症を止めること;
(iii)該疾患または状態を軽減すること、すなわち、該疾患または状態の後退をもたらすこと;あるいは
(iv)該疾患または状態に起因する症状を軽減すること、すなわち、根源的な疾患または状態に取り組まずに痛みを軽減することを含む。本明細書において使用される場合、用語「疾患」および「状態」は互換的に使用され得るか、あるいは、具体的な疾病または状態が既知の原因因子を有していなくともよく(その結果、病因がまだ解明されていない)、したがって、それはまだ疾患と認識されていないが単に望ましくない状態または症候群とだけ認識されており、臨床医によって多かれ少なかれ具体的な1セットの症状が確認されているという点で異なり得る。
I.化合物
R1、R2、またはR3のうちの1つは−P(=O)(OH)2であり、R1、R2、およびR3のうちの他の2つはそれぞれHである、化合物、またはその立体異性体、互変異性体、もしくは薬学的に許容され得る塩を提供する。
方法
アルボシジブプロドラッグの薬物動態学的プロフィール
n.e.=未評価
実施例3
動力学的溶解度プロフィール
血漿安定性プロフィール
化合物IB’の血漿安定性を、4種由来の血漿を使用して決定した。マウス、ラット、イヌ、およびヒトの結果を、表5、6、7、および8にそれぞれ示す。アルボシジブおよびフルマゼニルをコントロールとして使用した。マウス、ラット、およびヒトの血漿では、化合物IB’は、5時間のインキュベーション後に安定性が100%維持された。イヌ血漿では、5時間後におよそ90%の化合物IB’が残存した。比較すると、アルボシジブは、5時間後に4種全てにわたって100%安定性を維持し、フルマゼニルはマウスおよびラットの血漿で不安定であった。
スプレーグ・ドーリーラットにおける薬物動態学
マウスにおける最大忍容急性用量
SCIDマウスを処置群あたり3匹使用して行った。動物を、45、30、15、または7.5mg/kgの単一用量の化合物IB’を使用して処置した。比較のために、さらなる動物を同一の用量レベルのアルボシジブで処置した。経口投与後(図2A〜B)および静脈内(IV)投与後(図2C〜D)の体重測定を死亡率および臨床所見と共に使用して、最大忍容急性用量(MTDacute)を決定した。
実施例7
マウスにおける最大忍容反復用量スケジュール
ラットにおける最大忍容急性用量
マウス異種移植片有効性研究
マウス異種移植片薬力学研究
Claims (30)
- 前記医薬組成物が、錠剤として製剤化される、請求項1に記載の医薬組成物。
- 前記医薬組成物が、カプセル剤として製剤化される、請求項1に記載の医薬組成物。
- 前記薬学的に許容され得る担体または賦形剤が、ラクトースを含む、請求項1〜3のいずれか1項に記載の医薬組成物。
- 前記薬学的に許容され得る担体または賦形剤が、微晶質セルロースを含む、請求項1〜4のいずれか1項に記載の医薬組成物。
- 流動促進剤をさらに含む、請求項1〜5のいずれか1項に記載の医薬組成物。
- 前記流動促進剤が、コロイド状二酸化珪素を含む、請求項6に記載の医薬組成物。
- 滑沢剤をさらに含む、請求項1〜7のいずれか1項に記載の医薬組成物。
- 前記滑沢剤が、ステアリン酸マグネシウムを含む、請求項8に記載の医薬組成物。
- 医薬組成物が、錠剤またはカプセル剤として製剤化される、請求項10に記載の医薬組み合わせ物。
- 医薬組成物が、薬学的に許容され得る担体または賦形剤を含む、請求項10に記載の医薬組み合わせ物。
- 前記薬学的に許容され得る担体または賦形剤が、ラクトースを含む、請求項12に記載の医薬組み合わせ物。
- 前記薬学的に許容され得る担体または賦形剤が、微晶質セルロースを含む、請求項12または13に記載の医薬組み合わせ物。
- 前記医薬組成物が、流動促進剤をさらに含む、請求項12〜14のいずれか1項に記載の医薬組み合わせ物。
- 前記流動促進剤が、コロイド状二酸化珪素を含む、請求項15に記載の医薬組み合わせ物。
- 前記医薬組成物が、滑沢剤をさらに含む、請求項12〜15のいずれか1項に記載の医薬組み合わせ物。
- 前記滑沢剤が、ステアリン酸マグネシウムを含む、請求項17に記載の医薬組み合わせ物。
- 前記疾患ががんである、請求項10〜18のいずれか1項に記載の医薬組み合わせ物。
- 前記がんが血液学的がんである、請求項19に記載の医薬組み合わせ物。
- 前記血液学的がんが、急性骨髄白血病(AML)、多発性骨髄腫、濾胞性リンパ腫、急性リンパ芽球性白血病(ALL)、慢性リンパ性白血病(CLL)、および非ホジキンリンパ腫から選択される、請求項20に記載の医薬組み合わせ物。
- 前記血液学的がんが急性骨髄白血病(AML)である、請求項21に記載の医薬組み合わせ物。
- 前記血液学的がんが慢性リンパ性白血病(CLL)である、請求項21に記載の医薬組み合わせ物。
- 前記血液学的がんが多発性骨髄腫である、請求項21に記載の医薬組み合わせ物。
- 前記血液学的がんが骨髄異形成症候群(MDS)である、請求項20に記載の医薬組み合わせ物。
- 前記がんが固形腫瘍がんである、請求項19に記載の医薬組み合わせ物。
- 前記固形腫瘍がんが乳がん、前立腺がん、または結腸がんである、請求項26に記載の医薬組み合わせ物。
- 前記固形腫瘍がんが***、前立腺または結腸の腺癌である、請求項27に記載の医薬組み合わせ物。
- 前記固形腫瘍がんが胆管種である、請求項26に記載の医薬組み合わせ物。
- 前記化合物またはその互変異性体、もしくはその薬学的に許容され得る塩が、経口投与されることを特徴とする、請求項10〜29のいずれか1項に記載の医薬組み合わせ物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021079708A JP7133680B2 (ja) | 2015-05-18 | 2021-05-10 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562163188P | 2015-05-18 | 2015-05-18 | |
US62/163,188 | 2015-05-18 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018153504A Division JP6695940B2 (ja) | 2015-05-18 | 2018-08-17 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021079708A Division JP7133680B2 (ja) | 2015-05-18 | 2021-05-10 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020128387A JP2020128387A (ja) | 2020-08-27 |
JP6883688B2 true JP6883688B2 (ja) | 2021-06-09 |
Family
ID=56087537
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017559812A Active JP6510075B2 (ja) | 2015-05-18 | 2016-05-18 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
JP2018153504A Active JP6695940B2 (ja) | 2015-05-18 | 2018-08-17 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
JP2020075973A Active JP6883688B2 (ja) | 2015-05-18 | 2020-04-22 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
JP2021079708A Active JP7133680B2 (ja) | 2015-05-18 | 2021-05-10 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017559812A Active JP6510075B2 (ja) | 2015-05-18 | 2016-05-18 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
JP2018153504A Active JP6695940B2 (ja) | 2015-05-18 | 2018-08-17 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021079708A Active JP7133680B2 (ja) | 2015-05-18 | 2021-05-10 | バイオアベイラビリティが高いアルボシジブプロドラッグ |
Country Status (20)
Country | Link |
---|---|
US (5) | US9758539B2 (ja) |
EP (3) | EP4086264B1 (ja) |
JP (4) | JP6510075B2 (ja) |
KR (1) | KR102608921B1 (ja) |
CN (2) | CN111349118B (ja) |
AU (2) | AU2016264212B2 (ja) |
BR (1) | BR112017024933A8 (ja) |
CA (1) | CA2985804A1 (ja) |
CY (1) | CY1121851T1 (ja) |
DK (2) | DK3298021T3 (ja) |
ES (2) | ES2739749T3 (ja) |
HK (1) | HK1251941B (ja) |
HU (1) | HUE045585T2 (ja) |
IL (1) | IL255465B (ja) |
MX (1) | MX2017014645A (ja) |
PL (1) | PL3298021T3 (ja) |
PT (1) | PT3298021T (ja) |
RU (1) | RU2752729C2 (ja) |
TR (1) | TR201911032T4 (ja) |
WO (1) | WO2016187316A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970205B1 (en) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
BR112017011213A2 (pt) | 2014-12-23 | 2018-02-14 | Automed Pty Ltd | aparelho de fornecimento, sistema e métodos associados |
KR20180018507A (ko) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측 |
MX2017014645A (es) | 2015-05-18 | 2018-01-23 | Tolero Pharmaceuticals Inc | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. |
WO2017024073A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
WO2018094275A1 (en) * | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
CN110234659A (zh) | 2016-12-19 | 2019-09-13 | 特雷罗药物股份有限公司 | 用于敏感性分析的分析肽和方法 |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
US20190314357A1 (en) * | 2018-04-13 | 2019-10-17 | Tolero Pharmaceuticals, Inc. | Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer |
US20210277037A1 (en) * | 2018-06-21 | 2021-09-09 | Sumitomo Dainippon Pharma Oncology, Inc. | Deuterated alvocidib and alvocidib prodrugs |
CN112512597A (zh) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂 |
CA3119807A1 (en) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
AU2019395100A1 (en) * | 2018-12-07 | 2021-06-03 | Sumitomo Pharma Oncology, Inc. | Methods for treating castration-resistant and castration- sensitive prostate cancer |
TW202038957A (zh) | 2018-12-21 | 2020-11-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與激酶抑制劑之組合 |
JP2022525149A (ja) * | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
KR20210141621A (ko) | 2019-03-22 | 2021-11-23 | 스미토모 다이니폰 파마 온콜로지, 인크. | Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법 |
JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー, インコーポレイテッド | チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用 |
WO2021007316A1 (en) | 2019-07-08 | 2021-01-14 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of cancer |
WO2021113688A1 (en) | 2019-12-05 | 2021-06-10 | Sumitomo Dainippon Pharma Oncology, Inc. | Combination therapies for treatment of myelodysplastic syndrome |
AU2022333595A1 (en) | 2021-08-23 | 2024-03-28 | Sumitomo Pharma Co., Ltd. | Self degradation-type cdk9 inhibitor prodrug and liposome encapsulating same |
Family Cites Families (191)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2338043A1 (fr) | 1976-01-13 | 1977-08-12 | Delmar Chem | Derives de 4-arylpiperidine et procedes de production |
US4132710A (en) | 1976-12-20 | 1979-01-02 | Ayerst, Mckenna And Harrison, Ltd. | [2]Benzopyrano[3,4-c]pyridines and process therefor |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IN164232B (ja) | 1986-04-11 | 1989-02-04 | Hoechst India | |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP2691986B2 (ja) | 1987-08-28 | 1997-12-17 | チッソ株式会社 | ピリジン骨格を有する光学活性化合物の製造法 |
DE3743824C2 (de) | 1987-12-23 | 1997-03-06 | Hoechst Ag | Verfahren zur enzymatischen Racematspaltung von racemischen Alkoholen mit/in Vinylestern durch Umesterung |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3836676A1 (de) | 1988-10-28 | 1990-05-03 | Hoechst Ag | Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel |
US5284856A (en) | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JPH0641075A (ja) | 1990-09-01 | 1994-02-15 | Kazuo Achinami | 新規な1,4−ジヒドロピリジン化合物及びその製造方法 |
EP0507278A3 (en) | 1991-04-02 | 1993-12-15 | Hoechst Ag | Immobilised biocatalyser, its preparation and use for ester synthesis in a column reactor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
GB9422836D0 (en) | 1994-11-11 | 1995-01-04 | Wainscoat James | Monitoring malignant disease |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
CN1208438A (zh) | 1995-07-28 | 1999-02-17 | 玛丽·柯里癌症治疗中心 | 转运蛋白及其应用 |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
WO1997030174A1 (en) | 1996-02-20 | 1997-08-21 | Sloan-Kettering Institute For Cancer Research | Combinations of pkc inhibitors and therapeutic agents for treating cancers |
PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
US6087366A (en) | 1996-03-07 | 2000-07-11 | The Trustees Of Columbia University In The City Of New York | Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
TR199900066T2 (xx) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
PL335027A1 (en) | 1997-02-03 | 2000-03-27 | Pfizer Prod Inc | Derivatives of arylsulphonylamino hydroxamic acid |
DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
EP0984930B1 (en) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
WO1998054093A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
KR100372138B1 (ko) | 1997-08-08 | 2003-02-14 | 화이자 프로덕츠 인코포레이티드 | 아릴옥시아릴설포닐아미노 하이드록삼산 유도체 |
AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
US7064193B1 (en) | 1997-09-17 | 2006-06-20 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
AU9402898A (en) | 1997-09-26 | 1999-04-23 | Washington University | Cell death agonists |
SK6652000A3 (en) | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
DE19802449A1 (de) | 1998-01-23 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin |
US6437136B2 (en) | 1998-01-23 | 2002-08-20 | Aventis Pharma Deutschland Gmbh | Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
DE19809649A1 (de) | 1998-03-06 | 1999-09-09 | Hoechst Marion Roussel De Gmbh | Verfahren zur enzymatischen Enantiomeren-Trennung von 3(R)- und 3(S)-Hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridin bzw. der Carbonsäureester |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
IL139934A (en) | 1998-05-29 | 2007-10-31 | Sugen Inc | History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
FR2780056B1 (fr) | 1998-06-18 | 2000-08-04 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives de la 4-phenyl-1-2 3,6-tetrahydropyridine et les produits imtermediaires mis en oeuvre |
ES2235499T3 (es) | 1998-07-30 | 2005-07-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena. |
US6268499B1 (en) | 1998-08-10 | 2001-07-31 | Hoffman-La Roche Inc. | Process and intermediates for preparation of substituted piperidine-epoxides |
WO2000012071A2 (de) | 1998-08-29 | 2000-03-09 | Miklos Ghyczy | Pharmazeutisches und/oder diätetisches produkt |
PT1004578E (pt) | 1998-11-05 | 2004-06-30 | Pfizer Prod Inc | Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
WO2000059526A1 (en) | 1999-04-07 | 2000-10-12 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
WO2001012661A2 (en) | 1999-08-16 | 2001-02-22 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health | RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS |
US6821990B2 (en) | 2000-01-18 | 2004-11-23 | Aventis Pharma Deutschland Gmbh | Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one |
US6576647B2 (en) | 2000-01-18 | 2003-06-10 | Aventis Pharmaceuticals Inc. | Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one |
MY130363A (en) | 2000-02-15 | 2007-06-29 | Sugen Inc | "pyrrole substituted 2-indolinone protein kinase inhibitors" |
WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
US6849631B2 (en) | 2000-12-08 | 2005-02-01 | Bristol Myers Squibb Pharma Company | Semicarbazides and their uses |
AU2002258399A1 (en) | 2001-02-16 | 2002-09-19 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
EP1427407A4 (en) | 2001-03-23 | 2005-05-11 | Luitpold Pharm Inc | CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS |
US7816398B2 (en) | 2001-03-23 | 2010-10-19 | Luitpold Pharmaceuticals, Inc. | Fatty alcohol drug conjugates |
KR20030026069A (ko) | 2001-09-24 | 2003-03-31 | 주식회사 엘지생명과학 | 티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물 |
WO2003027237A2 (en) | 2001-09-24 | 2003-04-03 | Blood Center Research Foundation | Method of modulating or examining ku70 levels in cells |
AU2002361589A1 (en) | 2001-11-06 | 2003-05-19 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
AU2002364364A1 (en) | 2001-12-31 | 2003-07-24 | Dana-Farber Cancer Institute, Inc. | Method of treating apoptosis and compositions thereof |
KR101002443B1 (ko) | 2002-03-01 | 2010-12-17 | 이뮤노메딕스, 인코오포레이티드 | Rs7 항체 |
US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
CA2496400A1 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
US20070032417A1 (en) | 2002-12-24 | 2007-02-08 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
EP1620109A2 (en) | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
GB0315259D0 (en) | 2003-06-30 | 2003-08-06 | Cyclacel Ltd | Use |
MEP31408A (en) * | 2003-07-18 | 2010-10-10 | Abgenix Inc | Specific binding agents to hepatocyte growth factor |
CN1302004C (zh) | 2003-08-22 | 2007-02-28 | 浙江海正药业股份有限公司 | 一种阿糖胞苷的制备方法 |
SI1680443T1 (sl) | 2003-11-05 | 2014-01-31 | Dana-Farber Cancer Institute, Inc. | Stabilizirani peptidi z alfa vijačnico in uporabe le-teh |
EP1793823B1 (en) * | 2004-09-21 | 2012-08-08 | Vion Pharmaceuticals, Inc. | Phosphate containing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents |
WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
WO2006101846A1 (en) | 2005-03-16 | 2006-09-28 | Aventis Pharmaceuticals Inc. | Dosing regimen of flavopiridol for treating cancer in particular cll |
WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
US7750000B2 (en) | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
CA2621820A1 (en) * | 2005-09-09 | 2007-03-15 | Jan Gunzinger | Isoquinolines derivatives as igf-1r inhibitors |
WO2007123791A2 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
US20090142337A1 (en) | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
US9360473B2 (en) | 2006-08-16 | 2016-06-07 | Eutropics Pharmaceuticals, Inc. | Assay system to identify therapeutic agents |
JP2010520222A (ja) | 2007-03-01 | 2010-06-10 | スーパージェン, インコーポレイテッド | ピリミジン−2,4−ジアミン誘導体およびjak2キナーゼ阻害剤としてのピリミジン−2,4−ジアミン誘導体の使用 |
GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
WO2008139271A2 (en) | 2007-05-15 | 2008-11-20 | Piramal Life Sciences Limited | A synergistic pharmaceutical combination for the treatment of cancer |
WO2009014642A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
WO2009042237A2 (en) | 2007-09-26 | 2009-04-02 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
CA2708264C (en) | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
WO2009100335A1 (en) * | 2008-02-08 | 2009-08-13 | Wyeth | Phosphate derivatives of substituted benzoxazoles |
WO2009137664A1 (en) | 2008-05-07 | 2009-11-12 | Eutropics Pharmaceuticals, Inc. | Antibodies specific to heterodimers of bcl-2 family and uses thereof |
AU2009259136B2 (en) | 2008-06-09 | 2014-09-25 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
US20100061982A1 (en) * | 2008-09-10 | 2010-03-11 | Wyeth | 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
EP2396427A1 (en) | 2009-02-11 | 2011-12-21 | Abbott Laboratories | Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers |
PL2396036T3 (pl) | 2009-02-13 | 2017-12-29 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
WO2011088137A2 (en) | 2010-01-12 | 2011-07-21 | H. Lee Moffitt Cancer Center & Research Institute | Bad pathway gene signature |
US8372819B2 (en) | 2010-04-11 | 2013-02-12 | Salk Institute For Biological Studies | Methods and compositions for targeting skip |
JP5935030B2 (ja) | 2010-05-14 | 2016-06-15 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 白血病を治療するための組成物および方法 |
SG180031A1 (en) | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
US8987271B2 (en) | 2010-12-22 | 2015-03-24 | Eutropics Pharmaceuticals, Inc. | 2,2′-biphenazine compounds and methods useful for treating disease |
EP2684167B1 (en) | 2011-03-08 | 2020-09-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
JP6200884B2 (ja) | 2011-06-14 | 2017-09-20 | ノバルティス アーゲー | 骨髄増殖性腫瘍などの癌の治療におけるパノビノスタットおよびルキソリチニブの組合せ |
EP2561867A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
US9012215B2 (en) | 2011-09-22 | 2015-04-21 | The Johns Hopkins University | Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research |
US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
WO2013082660A1 (en) | 2011-12-09 | 2013-06-13 | Alfred Health | Prediction method |
WO2013138702A2 (en) | 2012-03-15 | 2013-09-19 | Bristol-Myers Squibb Company | Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway |
CA2868081C (en) | 2012-03-20 | 2021-01-05 | Loren D. Walensky | Inhibition of mcl-1 and/or bfl-1/a1 |
EP3236262B1 (en) | 2012-05-10 | 2019-09-25 | Eutropics Pharmaceuticals, Inc. | Surrogate functional diagnostics test for cancer |
WO2013182519A1 (en) | 2012-06-04 | 2013-12-12 | Universitaet Basel | Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer |
WO2013188355A1 (en) | 2012-06-12 | 2013-12-19 | Merck Sharp & Dohme Corp. | Cdk inhibitor for treating refractory chronic lymphocytic leukemia |
WO2013188978A1 (en) | 2012-06-20 | 2013-12-27 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
WO2013192423A2 (en) | 2012-06-20 | 2013-12-27 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
AU2013317985B2 (en) | 2012-09-19 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Dynamic BH3 profiling |
US9241941B2 (en) | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
EP2906598A1 (en) | 2012-10-09 | 2015-08-19 | Igenica Biotherapeutics, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
US20140287932A1 (en) | 2012-10-25 | 2014-09-25 | Whitehead Institute For Biomedical Research | Super-enhancers and methods of use thereof |
WO2015010094A1 (en) | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
JP6663852B2 (ja) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Bh3プロファイリングの方法 |
WO2015047510A1 (en) | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
US10640803B2 (en) | 2013-10-30 | 2020-05-05 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
ES2818110T3 (es) | 2014-02-28 | 2021-04-09 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación que comprende dinaciclib |
WO2015161247A1 (en) | 2014-04-17 | 2015-10-22 | Igenica Biotherapeutics, Inc. | Humanized anti-c16orf54 antibodies and methods of use thereof |
EP3967709A1 (en) | 2014-09-17 | 2022-03-16 | Novartis AG | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
AU2015333689A1 (en) | 2014-10-14 | 2017-05-25 | The Regents Of The University Of California | Use of CDK9 and BRD4 inhibitors to inhibit inflammation |
MX2017005861A (es) | 2014-11-07 | 2017-06-26 | Tolero Pharmaceuticals Inc | Metodos para el control transcripcional objetivo en regiones del super mejorador. |
US10793915B2 (en) | 2015-01-12 | 2020-10-06 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
JP2018511594A (ja) | 2015-03-18 | 2018-04-26 | マサチューセッツ インスティテュート オブ テクノロジー | 選択的mcl−1結合ペプチド |
WO2016154380A1 (en) | 2015-03-24 | 2016-09-29 | Eutropics Pharmaceuticals, Inc. | Surrogate functional biomarker for solid tumor cancer |
WO2016161248A1 (en) | 2015-04-02 | 2016-10-06 | Tolero Pharmaceuticals, Inc. | Targeting pim kinases in combination with btk inhibition |
KR20180018507A (ko) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측 |
US20180120297A1 (en) | 2015-04-27 | 2018-05-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
MX2017014645A (es) | 2015-05-18 | 2018-01-23 | Tolero Pharmaceuticals Inc | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. |
WO2017024073A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
US20190077840A1 (en) | 2015-10-30 | 2019-03-14 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
CN105919955A (zh) | 2016-06-13 | 2016-09-07 | 佛山市腾瑞医药科技有限公司 | 一种鲁索利替尼制剂及其应用 |
WO2018094275A1 (en) * | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
CN110234659A (zh) | 2016-12-19 | 2019-09-13 | 特雷罗药物股份有限公司 | 用于敏感性分析的分析肽和方法 |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
CA3119807A1 (en) * | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
-
2016
- 2016-05-18 MX MX2017014645A patent/MX2017014645A/es unknown
- 2016-05-18 CN CN202010157126.5A patent/CN111349118B/zh active Active
- 2016-05-18 DK DK16725997.7T patent/DK3298021T3/da active
- 2016-05-18 DK DK19167051.2T patent/DK3527574T3/da active
- 2016-05-18 EP EP22166479.0A patent/EP4086264B1/en active Active
- 2016-05-18 HU HUE16725997A patent/HUE045585T2/hu unknown
- 2016-05-18 TR TR2019/11032T patent/TR201911032T4/tr unknown
- 2016-05-18 EP EP16725997.7A patent/EP3298021B1/en active Active
- 2016-05-18 US US15/158,206 patent/US9758539B2/en active Active
- 2016-05-18 RU RU2017143776A patent/RU2752729C2/ru active
- 2016-05-18 KR KR1020177036133A patent/KR102608921B1/ko active IP Right Grant
- 2016-05-18 AU AU2016264212A patent/AU2016264212B2/en active Active
- 2016-05-18 WO PCT/US2016/033099 patent/WO2016187316A1/en active Application Filing
- 2016-05-18 ES ES16725997T patent/ES2739749T3/es active Active
- 2016-05-18 EP EP19167051.2A patent/EP3527574B1/en active Active
- 2016-05-18 CA CA2985804A patent/CA2985804A1/en active Pending
- 2016-05-18 JP JP2017559812A patent/JP6510075B2/ja active Active
- 2016-05-18 PL PL16725997T patent/PL3298021T3/pl unknown
- 2016-05-18 PT PT16725997T patent/PT3298021T/pt unknown
- 2016-05-18 ES ES19167051T patent/ES2921350T3/es active Active
- 2016-05-18 BR BR112017024933A patent/BR112017024933A8/pt active Search and Examination
- 2016-05-18 CN CN201680028628.XA patent/CN107849073B/zh active Active
-
2017
- 2017-08-09 US US15/673,213 patent/US10259835B2/en active Active
- 2017-11-06 IL IL255465A patent/IL255465B/en unknown
-
2018
- 2018-08-17 JP JP2018153504A patent/JP6695940B2/ja active Active
- 2018-09-03 HK HK18111270.8A patent/HK1251941B/zh unknown
-
2019
- 2019-02-19 US US16/279,958 patent/US10562925B2/en active Active
- 2019-07-26 CY CY20191100801T patent/CY1121851T1/el unknown
- 2019-12-26 US US16/727,693 patent/US20200131210A1/en not_active Abandoned
-
2020
- 2020-04-22 JP JP2020075973A patent/JP6883688B2/ja active Active
-
2021
- 2021-01-20 AU AU2021200343A patent/AU2021200343A1/en not_active Abandoned
- 2021-05-07 US US17/314,896 patent/US20210261585A1/en active Pending
- 2021-05-10 JP JP2021079708A patent/JP7133680B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6883688B2 (ja) | バイオアベイラビリティが高いアルボシジブプロドラッグ | |
US11926640B2 (en) | Prodrugs of glutamine analogs | |
US11279694B2 (en) | Alvocidib prodrugs and their use as protein kinase inhibitors | |
TWI741501B (zh) | Fxr激動劑之固體形式 | |
WO2021110168A1 (zh) | 作为erk抑制剂的螺环类化合物及其应用 | |
ES2312978T3 (es) | Potenciador del efecto antitumoral y agente antitumoral. | |
JP7186874B2 (ja) | ピラゾリル化合物およびその使用方法 | |
JP2003300888A (ja) | 抗腫瘍効果増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200422 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20201002 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210315 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210316 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210510 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6883688 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |